Bmrn or expe which has an higher short term stock appreciation

**BioMarin Pharmaceutical (BMRN) has a higher short-term stock appreciation**, and here's why:

1. **Recent News**: BioMarin has recently presented new Phase 3 data highlighting the long-term safety and efficacy of its product ROCTAVIAN, which is a positive development for the company. This news could lead to increased investor confidence and potential stock appreciation.
2. **Stock Performance**: BioMarin's stock (BMRN) has shown a positive trend with a 5-day moving average of $83.80 and a 10-day moving average of $81.56, indicating a recent upward trend. Additionally, the company has a net fund flow of $96.88 million, which suggests strong investor interest.

|Ticker|Name|50-Day Moving Average|5-Day Moving Average|10-Day Moving Average|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|BMRN.O|Biomarin|82.7634|83.8010|81.5590|20240614|BMRN|185|

3. **Analyst Ratings**: BioMarin has an average price target of $97.75, with a "Buy" consensus rating, which suggests that analysts are optimistic about the stock's future performance.
4. **Comparison with Expedia**: In contrast, Expedia Group (EXPE) has a negative net fund flow of $-26.01 million and a 5-day moving average of $123.4, indicating a potential decline in stock price. Additionally, Expedia has a lower average price target of $144.77, with a "Neutral" consensus rating, suggesting that analysts may not be as optimistic about its short-term prospects.

|Ticker|Name|50-Day Moving Average|5-Day Moving Average|10-Day Moving Average|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|EXPE.O|Expedia|122.0805|123.4030|120.4365|20240614|EXPE|185|

In conclusion, based on recent news, stock performance, and analyst ratings, BioMarin Pharmaceutical (BMRN) has a higher potential for short-term stock appreciation compared to Expedia Group (EXPE). However, it's important to conduct thorough research and consider your own investment strategy before making any investment decisions.